A randomized phase II study of gemcitabine plus S-1 versus gemcitabine alone in patients with unresectable pancreatic cancer.

被引：0
|
作者：
Omuro, Y.
Ikari, T.
Ishii, H.
Ozaka, M.
Suyama, M.
Matsumura, Y.
Itoi, T.
Egawa, N.
Yano, S.
Hanada, K.
Kimura, Y.
Ukita, T.
Ishida, Y.
Tani, M.
Ohoka, S.
Hirose, Y.
Hijioka, S.
Watanabe, R.
Ikeda, T.
Nakajima, T.
机构：
[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[2] Tobu Chiiki Hosp, Tokyo, Japan
[3] Canc Inst Hosp, Tokyo, Japan
[4] Canc Inst Hosp, Dept Med Oncol, Tokyo, Japan
[5] Juntendo Univ Hosp, Tokyo, Japan
[6] Tokyo Med Univ, Tokyo 1608402, Japan
[7] Kanazawa Univ, Kanazawa, Ishikawa, Japan
[8] JA Onomichi Gen Hosp, Hiroshima, Japan
[9] Sapporo Med Univ Hosp, Sapporo, Hokkaido, Japan
[10] Toho Univ, Ohashi Med Ctr, Tokyo, Japan
[11] Kurume Univ Hosp, Kurume, Fukuoka, Japan
[12] Wakayama Med Univ Hosp, Wakayama, Japan
[13] Tokyo Med & Dent Univ Hosp, Tokyo, Japan
[14] Fukui Red Cross Hosp, Fukui, Japan
[15] Kumamoto Red Cross Hosp, Kumamoto, Japan
[16] Matsuyama Shimin Hosp, Matsuyama, Japan
[17] Yokosuka Kyosai Hosp, Yokosuka, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4029
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.
    Imaoka, Hiroshi
    Kou, Tadayuki
    Tanaka, Masao
    Egawa, Shinichi
    Mizuno, Nobumasa
    Hijioka, Susumu
    Hara, Kazuo
    Yazumi, Shujiro
    Shimizu, Yasuhiro
    Yamao, Kenji
    EUROPEAN JOURNAL OF CANCER, 2016, 54 : 96 - 103
  • [22] A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer
    Ueno, M.
    Okusaka, T.
    Omuro, Y.
    Isayama, H.
    Fukutomi, A.
    Ikeda, M.
    Mizuno, N.
    Fukuzawa, K.
    Furukawa, M.
    Iguchi, H.
    Sugimori, K.
    Furuse, J.
    Shimada, K.
    Ioka, T.
    Nakamori, S.
    Baba, H.
    Komatsu, Y.
    Takeuchi, M.
    Hyodo, I.
    Boku, N.
    ANNALS OF ONCOLOGY, 2016, 27 (03) : 502 - 508
  • [23] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
    Morizane, C.
    Okusaka, T.
    Furuse, J.
    Ishii, H.
    Ueno, H.
    Ikeda, M.
    Najima, M.
    Hirokawa, S.
    Nakachi, K.
    Ogura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 206S - 206S
  • [24] Updated results of a phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer.
    Han, Boram
    Kim, Hyeong Su
    Choi, Dae Ro
    Shim, Byoung Yong
    Lee, Kyung Hee
    Kim, Jin Won
    Kim, Jung Han
    Kim, Jung Hoon
    Kim, Ho Young
    Song, Hunho
    Park, Choong Kee
    Moon, Sung Hoon
    Kim, Jong Hyeok
    Jeon, Jang Yong
    Lee, Jung Woo
    Zang, Dae Young
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] A phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
    Nakachi, K.
    Okusaka, T. O.
    Funakoshi, A. F.
    Ioka, T. I.
    Yamao, K. Y.
    Ohkawa, S. O.
    Boku, N. B.
    Komatsu, Y. K.
    Nakamori, S. N.
    Furuse, J. F.
    EJC SUPPLEMENTS, 2009, 7 (02): : 387 - 387
  • [26] Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
    Okusaka, Takuji
    Furuse, Junji
    Funakoshi, Akihiro
    Ioka, Tatsuya
    Yamao, Kenji
    Ohkawa, Shinichi
    Boku, Narikazu
    Komatsu, Yoshito
    Nakamori, Shoji
    Iguchi, Haruo
    Ito, Tetsuhide
    Nakagawa, Kazuhiko
    Nakachi, Kohei
    CANCER SCIENCE, 2011, 102 (02) : 425 - 431
  • [27] A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
    Oettle, H
    Richards, D
    Ramanathan, RK
    van Laethem, JL
    Peeters, M
    Fuchs, M
    Zimmermann, A
    John, W
    Von Hoff, D
    Arning, M
    Kindler, HL
    ANNALS OF ONCOLOGY, 2005, 16 (10) : 1639 - 1645
  • [28] Phase II study of combination chemotherapy of gemcitabine/S-1 with nafamostat mesilate for advanced unresectable pancreatic cancer. First report
    Uwagawa, T.
    Sakamoto, T.
    Nakaseko, Y.
    Takano, Y.
    Furukawa, K.
    Kanehira, M.
    Onda, S.
    Gocho, T.
    Shiba, H.
    Arakawa, Y.
    Aiba, K.
    Yanaga, K.
    ANNALS OF ONCOLOGY, 2016, 27 : 34 - 34
  • [29] Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT)
    Haas, M.
    Waldschmidt, D.
    Stahl, M.
    Reinacher-Schick, A.
    Freiberg-Richter, J.
    Kaiser, F.
    Kanzler, S.
    Frickhofen, N.
    Seufferlein, T.
    Dechow, T.
    Mahlberg, R. J. C.
    Malfertheiner, P.
    Illerhaus, G.
    Kubicka, S.
    Held, S.
    Westphalen, C. B.
    Kruger, S.
    Boeck, S.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2018, 29 : 243 - 243
  • [30] A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer
    Han, Boram
    Kim, Bum Jun
    Kim, Hyeong Su
    Choi, Dae Ro
    Shim, Byoung Yong
    Lee, Kyung Hee
    Kim, Jin Won
    Kim, Jung Han
    Song, Hunho
    Kim, Jong Hyeok
    Park, Choong Kee
    Lee, Jung Woo
    Kim, Min-Jeong
    Zang, Dae Young
    JOURNAL OF CANCER, 2021, 12 (03): : 912 - 917
12345